Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The clinical utility of plasma circulating tumor DNA in the diagnosis and disease surveillance in non-diffuse large B-cell non-Hodgkin lymphomas.

Future oncology (London, England) - 1 Jan 2024

Zhang Xiaoping, Yang Li, Zhu Minyi, Zhao Xiaotian, Xiao Yao, Pang Jiaohui, Zhu Liuqing, Ou Qiuxiang, Ni Hai-Wen, Xu Jingyan

Abstract excerpt

Aim: Advances in circulating tumor DNA (ctDNA) analysis for diffuse large B-cell lymphoma (DLBCL) have prompted the evaluation of its utility in other non-Hodgkin lymphomas (NHLs), leading to significant insights into its potential applications.Methods: We retrospectively studied paired plasma and tissue/bone marrow biopsies of 203 non-DLBCL NHLs [87 follicular lymphomas (FL), 64 mantle cell lymphomas (MCL), 30...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Circulating Tumor DNA

Share to High-Throughput Nucleotide Sequencing

Share to Lymphoma, Large B-Cell, Diffuse

Share to Lymphoma, Non-Hodgkin

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 39417339
DOI: 10.1080/14796694.2024.2402209
PMCID: PMC13179002

Genes

IGH
BCL2
CCND1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The clinical utility of plasma circulating tumor DNA in the diagnosis and disease surveillance in non-diffuse large B-cell non-Hodgkin lymphomas.PMID 39417339Read ↗

Circulating Tumor DNA as a Biomarker of Treatment Response and Minimal Residual Disease in Diffuse Large B-Cell Lymphoma: A Literature ReviewSemantic proximity Read ↗

Circulating tumor DNA as a powerful tool in diagnostics and treatment outcome prediction - focus on large B-cell lymphomas and follicular lymphomas.Semantic proximity Read ↗

Circulating tumor DNA assisting lymphoma genetic feature profiling and identification.Semantic proximity Read ↗

Circulating Tumor DNA in Lymphoma.Semantic proximity Read ↗

Clinical use of circulating tumor DNA analysis in patients with lymphomaSemantic proximity Read ↗

Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.Semantic proximity Read ↗

Circulating Tumor DNA in Lymphoma: Principles and Future DirectionsSemantic proximity Read ↗

The value of liquid biopsy in diagnosis and monitoring of diffuse large b-cell lymphoma: recent developments and future potential.Semantic proximity Read ↗

The DIRECT study: A roadmap for ctDNA-based risk prediction, molecular profiling and MRD detection in Diffuse Large B Cell LymphomaSemantic proximity Read ↗

Circulating Tumor DNA Assessment in Classic Hodgkin Lymphoma: Ready for Primetime?Semantic proximity Read ↗

Mutation profiling of circulating tumor DNA identifies distinct mutation patterns in non-Hodgkin lymphoma.Semantic proximity Read ↗

Circulating tumour DNA in B‐cell lymphomas: current state and future prospectsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.